Deals & Cases


On July 6, 2020, Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin® therapeutics, successfully completed a private placement with institutional investors of 5,528,089 shares newly issued out of its authorized share capital by way of an accelerated bookbuilding. The shares were placed at CHF 14.50 per share, resulting in gross proceeds of approximately CHF 80.2 m.

Molecular Partners was advised by Homburger in this transaction. The Homburger team was led by partner Dieter Gericke (Corporate | M&A) and included partner Dieter Grünblatt (Tax) and associates Karin Mattle and Lorenzo Togni (both Corporate | M&A).